DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Pharmacogenetic Study of Obsessive-Compulsive Disorder

Information source: Severance Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Obsessive-Compulsive Disorder

Intervention: SSRIs (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Severance Hospital

Official(s) and/or principal investigator(s):
Se Joo Kim, M.D., Principal Investigator, Affiliation: Professor, Department of Psychiactry, Yonsei Univ. College of Medicine

Overall contact:
Se Joo Kim, M.D., Phone: +82-2-2228-1627, Email: kimsejoo@yuhs.ac


The purpose of this study is to determine whether pharmacogenetic study predict selective serotonin reuptake inhibitor (SSRI) responsiveness in advance before the appearance of the drug effect until 4 months(16 weeks), 6 months, and 1 year after administration of SSRIs.

Clinical Details

Official title: Pharmacogenetic Study of Obsessive-Compulsive Disorder

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label

Primary outcome: Change from baseline in the Yale-Brown Obsessive-Compulsive Scale

Secondary outcome:

Change from the baseline Montgomery-Asberg Depression Rating Scale

Occurrence of any side effects during the SSRIs treatment

Detailed description: The purpose of this study is to determine the effects of genetic variants on the response to SSRIs in obsessive-compulsive disorder (OCD) subject. The investigators will recruit drug-naive or drug-free(> 3 months) OCD subjects (n=200). The participants will get SSRIs for their OCD symptoms. The type and dose of SSRIs will not be restricted and will depend on the individual participant's state. However, the investigators will be recommended to follow usual clinical guideline (the Korean treatment algorithm for OCD, 2004). At baseline, 4 month, 6 months, and 1 year after treatment, the participants will be evaluated by Yale-Brown Obsessive-Compulsive Scale(YBOCS), Montgomery Asberg Depression Rating Scale(MADRS), Dimensional Obsessive-Compulsive Scale(DOCS), Toronto alexithymia scale (TAS), interpersonal reactivity index (IRI), Barratt impulsiveness scale (BIS), and the Measure of Constructs Underlying Perfectionism(M-CUP). And all the participants will donate 5 ml of whole blood and DNA will be extracted. Using various genetic analyses methods such as genotyping, exome sequencing, and so on we will analyze the association of various genetic variants and the anti-obsessive-compulsive responses.


Minimum age: 19 Years. Maximum age: 60 Years. Gender(s): Both.


Inclusion Criteria: 1. age 19~ 60 2. OCD by Diagnostic and Statistical Manual for Mental disorders, 4th edition (DSM-IV) 3. drug naive or drug free for more than 3 months Exclusion Criteria: 1. any neurological disorder 2. comorbid psychotic disorders 3. alcohol or other substance dependence within past 6 months 4. any evidences for brain diseases

Locations and Contacts

Se Joo Kim, M.D., Phone: +82-2-2228-1627, Email: kimsejoo@yuhs.ac

Yonsei Univ. Health System Severance Hospital, Seoul 120-752, Korea, Republic of; Recruiting
Se Joo Kim, M.D., Phone: +82-2-2228-1620, Email: kimsejoo@yuhs.ac
Jee In Kang, M.D., Phone: +82-2-2228-1620, Email: kji0354@yahoo.co.kr
Se Joo Kim, M.D., Principal Investigator
Jee In Kang, M.D., Sub-Investigator
Additional Information

Starting date: January 2013
Last updated: April 27, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017